Shares of Ultragenyx Pharmaceutical Inc fell 3% after the company resubmitted its application for a gene therapy to treat Sanfilippo syndrome. The drug was earlier rejected by the United States Food and Drug Administration, which asked for more data. Ultragenyx now expects a decision in 2026, keeping various investors cautious.